Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Nebozhyn

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor TypesRazvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinomaAnil Vachani, Michael Nebozhyn, Sunil Singhal, et al.
British Journal of Cancer|February 14, 2018
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinomaNatalie Cook, Bristi Basu, Donna-Michelle Smith, et al.
NPJ Breast Cancer|October 2, 2025
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapyJavier Cortes, Oleg Lipatov, Seock-Ah Im, et al.
Molecular Cancer Therapeutics|June 4, 2016
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to VintafolideAmy D Guertin, Jennifer O'Neil, Alexander Stoeck, et al.
Pediatric Blood & Cancer|July 1, 2016
A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcomaPeter M Anderson, Stefan S Bielack, Richard G Gorlick, et al.
Journal for Immunotherapy of Cancer|July 3, 2023
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trialKohei Shitara, Maria Di Bartolomeo, Mario Mandala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group studyEvanthia Galanis, Kurt A Jaeckle, Matthew J Maurer, et al.
International Journal of Cancer|September 30, 2016
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trialFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.
Journal of the National Cancer Institute|September 26, 2015
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal CancerFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor TypesRazvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinomaAnil Vachani, Michael Nebozhyn, Sunil Singhal, et al.
British Journal of Cancer|February 14, 2018
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinomaNatalie Cook, Bristi Basu, Donna-Michelle Smith, et al.
NPJ Breast Cancer|October 2, 2025
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapyJavier Cortes, Oleg Lipatov, Seock-Ah Im, et al.
Molecular Cancer Therapeutics|June 4, 2016
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to VintafolideAmy D Guertin, Jennifer O'Neil, Alexander Stoeck, et al.
Pediatric Blood & Cancer|July 1, 2016
A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcomaPeter M Anderson, Stefan S Bielack, Richard G Gorlick, et al.
Journal for Immunotherapy of Cancer|July 3, 2023
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trialKohei Shitara, Maria Di Bartolomeo, Mario Mandala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group studyEvanthia Galanis, Kurt A Jaeckle, Matthew J Maurer, et al.
International Journal of Cancer|September 30, 2016
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trialFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.
Journal of the National Cancer Institute|September 26, 2015
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal CancerFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.
Pageof 4